<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286909</url>
  </required_header>
  <id_info>
    <org_study_id>OP912011</org_study_id>
    <nct_id>NCT01286909</nct_id>
  </id_info>
  <brief_title>Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)</brief_title>
  <acronym>LaFlavon</acronym>
  <official_title>Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omicron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omicron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in
      Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in High-Density Lipoprotein (HDL)</measure>
    <time_frame>Change from Baseline in High-Density Lipoprotein (HDL) at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of liver enzymes</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>LaFlavon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LaFlavon</intervention_name>
    <description>two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months</description>
    <arm_group_label>LaFlavon</arm_group_label>
    <other_name>Lycopene/Isoflavon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and Women with Metabolic Syndrome

          2. Elevated Triglycerides (&gt; 150)

          3. Low High-Density Lipoprotein (HDL) (&lt; 35)

          4. Willingness to take study nutritional supplement once a day for 3 months

        Exclusion Criteria:

          1. Women who are pregnant, nursing, or who intend pregnancy during the period of
             treatment

          2. Known milk, soy or whey allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Akram Echtay, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rafic Hariri University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Akram Echtay, M.D.</last_name>
    <phone>+9613856323</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanan Sdepanian</last_name>
    <phone>+9617098618</phone>
    <email>sanan_sdepanian@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rafic Hariri University Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Akram Echtaye, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Dr. Akram Echtaye, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <last_update_submitted>February 9, 2011</last_update_submitted>
  <last_update_submitted_qc>February 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Akram Echtay</name_title>
    <organization>Omicron Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Metabolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

